bnt-211
context therapuetics,biontech
['bnt211', 'ovarian', 'ca,022,i', 'ca,022,1', '$cntx', 'biontech']
biontech bnt211 #cldn6 car-t update at #asco2023 highlights: 75% orr at dl2 80% orr (4/5 pts) at dl2 in late-line ovarian cancer clinical validation with bnt211 now achieved in late-line ovarian and testicular (57% orr disclosed at #esmo2022) cancer. $cntx
CEO at @Context_Tx, $CNTX. BoD Praesidia BioTherapeutics and @CureDuchenne. Philly biotech champion.